Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...